Diagnosis of adenocarcinoma in prostate needle biopsy tissue

Journal of Clinical Pathology

Volumn 60, Issue 1, 2007, Pages 35-42

  Humphrey, P A ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHYLACYL COENZYME A RACEMASE; CYTOKERATIN; EOSIN; HEMATOXYLIN; KERATIN; KERATIN 34BETAE12; MUCIN; PROTEIN P63; UNCLASSIFIED DRUG;

ADENOCARCINOMA; BASAL CELL; CANCER GRADING; CRYSTALLOID; CYTOPLASM; DIAGNOSTIC PROCEDURE; DIFFERENTIAL DIAGNOSIS; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MITOSIS; NEEDLE BIOPSY; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROTEIN EXPRESSION; REVIEW;

ADENOCARCINOMA; BIOPSY, NEEDLE; DIAGNOSIS, DIFFERENTIAL; HUMANS; MALE; NEOPLASM INVASIVENESS; PROSTATE; PROSTATIC NEOPLASMS;

EID: 33846463004     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.2005.036442     Document Type: Review

References (74)

1. Parkin DM, Bray, F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
2. Humphrey PA. Clinical aspects of prostatic carcinoma, with histopathologic correlations. In: Prostate pathology. Chicago: ASCP Press, 2003:226-57.
3. Epstein JI, Walsh PC, Carmichael M, et al. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 1994;271:368-74.
4. Berger AP, Spranger R, Kofler K, et al. Early detection of prostate cancer with low PSA cut-off values leads to significant stage migration in radical prostatectomy specimens. Prostate 2003;57:93-8.
5. van der Cruijsen-Koeter IW, Vis AN, Roobol MJ, et al. Comparison of screen detected and clinically diagnosed prostate cancer in the European randomized study of screening for prostate cancer, section Rotterdam. J Urol 2005;174:121-5.
6. Thorson P, Vollmer RT, Arcangeli C, et al. Minimal carcinoma in prostate needle biopsy specimens: diagnostic features and radical prostatectomy follow-up. Mod Pathol 1998;11:543-51.
7. Iczkowski KA, Bostwick DG. Criteria for biopsy diagnosis of minimal volume prostatic adenocarcinoma: analytic comparison with nondiagnostic but suspicious atypical small acinar proliferation. Arch Pathol Lab Med 2000;124:98-107.
8. Totten RS, Heinemann MW, Hudson PB, et al. Microscopic differential diagnosis of latent carcinoma of prostate. Arch Pathol 1953;55:131-41.
9. Algaba F, Epstein JI, Aldape HC, et al. Assessment of prostate carcinoma in core needle biopsy-definition of minimal criteria for the diagnosis of cancer in biopsy material. Cancer 1996;78:376-81.
10. Epstein JI. Diagnostic criteria of limited adenocarcinoma of the prostate on needle biopsy. Hum Pathol 1995;26:223-9.
11. Humphrey PA. Gleason grading and prognostic factors in carcinoma of the prostate. Mod Pathol 2004;17:292-306.
12. Amin MB, Grignon DJ, Humphrey PA, et al. In: Gleason grading of prostate cancer. A contemporary approach Philadelphia: Lippincott Williams & Wilkins, 2004.
13. Epstein JI, Allsbrook WC Jr, Amin MB, et al. The 2005 international Society of Urological Pathology (ISUP) Consensus Conference on Gleason grading of prostatic carcinoma. Am J Surg Pathol 2005;29:1228-42.
14. Gleason DF. Histologic grading of prostatic carcinoma. In: Bostwick DG, ed. Pathology of the prostate. New York: Churchill Livingstone, 1990:83-93.
15. BostwicK DG. Gleason grading of prostatic needle biopsies. Correlation with grade in 316 matched prostatectomies. Am J Surg Pathol 1994;18:796-803.
16. Steinberg DM, Sauvageot J, Piantodosi S, et al. Correlation of prostate needle biopsy and radical prostatectomy Gleason grade in academic and community settings. Am J Surg Pathol 1997;21:566-76.
17. Ravery V, Boccon-Gibod LA, Dauge-Geffroy MC, et al. Systematic biopsies accurately predict extracapsular extension of prostate cancer and persistent/recurrent detectable PSA after radical prostatectomy. Urology 1994;44:371-6.
18. Bostwick DG, Dundore PA. Normal anatomy and histology. In. Biopsy pathology of the prostate. London: Chapman and Hall Medical, 1997-12.
19. Cleary KR, Choi HY, Ayalo AG. Basal cell hyperplasia of the prostate. Am J Clin Pathol 1983;80:850-4.
20. Devaraj LT, Bostwick DG. Atypical basal cell hyperplasia of the prostate. Immunophenotypic profile and proposed classification of basal cell proliferations. Am J Surg Pathol 1993;17:645-59.
21. Hedrick L, Epstein JI. Use of keratin 903 as an adjunct in the diagnosis of prostate carcinoma. Am J Surg Pathol 1989;13:389-96.
22. Varma M, Amin MB, Linden MD, et al. Discriminant staining patterns of small glandular and preneoplastic lesions of the prostate using high molecular weight cytokeratin (HMCK): a study of 301 consecutive needle Biopsies [abstract]. Mod Pathol 1997;10:93A.
23. Gaudin PB, Epstein JI. Adenosis of the prostate. Histologic features in needle biopsy specimens. Am J Surg Pathol 1995;19:737-47.
24. Bostwick DG, Srigley J, Grignon D, et al. Atypical adenomatous hyperplasia of the prostate: morphologic criteria for its distinction from well-differentiated carcinoma. Hum Pathol 1993;24:819-32.
25. Bostwick DG, Qian J, Ma J, et al. Mesonephric remnants of the prostate: incidence and histologic spectrum. Mod Pathol 2003;16:630-5.
26. Skinnider BF, Oliva E, Young RH, et al. Expression of alpha-methylacyl-CoA racemase (P504S) in nephrogenic adenoma: a significant immunohistochemical pitfall compounding the differential diagnosis with prostatic adenocarcinoma. Am J Surg Pathol 2004;28:701-5.
27. Gupta A, Wang HL, Policarpio-Nicolas ML, et al. Expression of alpha-methylacyl coenzyme A racemase in nephrogenic adenoma. Am J Surg Pathol 2004;28:1224-9.
28. Herawi M, Parwani AV, Irie J, et al. Small glandular proliferations: most common benign mimickers of prostatic adenocarcinoma sent for expert second opinion. Am J Surg Pathol 2005;29:874-80.
29. Hameed O, Humphrey PA. Immunohistochemistry in diagnostic surgical pathology of the prostate. Semin Diagn Pathol 2005;22:88-104.
30. Nelson RS, Epstein JI. Prostatic carcinoma with abundant xanthomatous cytoplasm. Foamy gland carcinoma. Am J Surg Pathol 1996;20:419-26.
31. Reuter VE. Pathological changes in benign and malignant tissue following androgen deprivation therapy. Urology 1997;49(Suppl 3A):16-22
32. Kramer CE, Epstein JI. Nucleoli in low-grade prostate adenocarcinoma and adenosis. Hum Pathol 1993;24:618-23.
33. Epstein JI, Herawi M. Prostate needle biopsies containing prostatic intraepithelial neoplasia or atypical foci suspicious for carcinoma: implications for patient care J Urol 2006;175:820-34.
34. Baisden BL, Kahane H, Epstein JI. Perineural invasion, mucinous fibroplasia, and glomerulations: diagnostic features of limited cancer on prostate needle biopsy. Am J Surg Pathol 1999;23:918-24.
35. Bostwick DG, Wollan P, Adlakha K. Collagenous micronodules in prostate cancer. A specific but infrequent diagnostic finding. Arch Pathol Lab Med 1995;119:444-7
36. Pacelli A, Lopez-Beltran A, Egan AJ, et al. Prostatic adenocarcinoma with glomeruloid features. Hum Pathol 1998;29:543- 6.
37. Humphrey PA. Adenocarcinoma In: Prostate pathology. Chicago: ASCP Press, 2003:259-337.
38. Carstens PHB. Perineural glands in normal and hyperplastic prostate. J Urol 1989;123:686-8.
39. McIntire TL, Franzini DA. The presence of benign prostatic glands in perineural spaces. J Urol 1986;135:507-9.
40. Ali TZ, Epstein JI. Perineural involvement by benign prostatic glands on needle biopsy. Am J Surg Pathol 2005;29:1159-63.
41. Young RH. Pseudoneoplastic lesions of the urinary bladder, prostate gland, and urethra. In: Wick MR, Humphrey PA, Ritter JR, eds. Pathology of pseudoneoplastic lesions. New York: Lippincott-Raven, 1997:223-35.
42. Srigley JR. Benign mimickers of prostatic adenocarcinoma. Mod Pathol 2004;17:328-48.
43. Humphrey PA. Focal glandular atypia. In: Prostate pathology. Chicago: ASCP Press, 2003:218-25.
44. Oliai BR, Kahane H, Epstein JI. A clinicopathologic analysis of urothelial carcinomas diagnosed on prostate needle biopsy. Am J Surg Pathol 2001;25:794-801.
45. Wojno KJ, Epstein JI. The utility of basal cell-specific anti-cytokeratin antibody (34 beta E12) in the diagnosis of prostate cancer. A review of 228 cases. Am J Surg Pathol 1995;19:251-60.
46. Browne TJ, Hirsch MS, Brodsky G, et al. Prospective evaluation of AMACR (P504S) and basal cell markers in the assessment of routine needle biopsy specimens. Hum Pathol 2004;35:1462-8.
47. Amin MB, Schultz DS, Zarbo RJ. Analysis of cribriform morphology in prostatic neoplasia using antibody to high-molecular-weight cytokeratins. Arch Pathol Lab Med 1994;118:250-64.
48. Kahane H, Sharp JW, Shuman GB, et al. Utilization of high molecular weight cytokeratin on prostate needle biopsies in an independent laboratory. Urology 1995;45:981-6.
49. Martens MB, Keller JH. Routine immunohistochemical staining for high-molecular weight cytokeratin 34-beta and alpha-methylacyl CoA racemase (P504S) in postirradiation prostate biopsies. Mod Pathol 2006;19:287-90.
50. Gaudin PB. Histopathologic effects of radiation and hormonal therapies on benign and malignant prostate tissues. J Urol Pathol 1988;8:55-67.
51. Parsons JK, Gage WR, Nelson WG, et al. p63 protein expression is rare in prostate adenocarcinoma: implications for cancer diagnosis and carcinogenesis. Urology 2001;58:619-24.
52. Signoretti S, Waltregny D, Dilks J, et al. p63 is a prostate basal cell marker and is required for prostate development. Am J Pathol 2000;157:1769-75.
53. Abrahams NA, Ormsby AH, Brainard J. Validation of cytokeratin 5/6 as an effective substitute for keratin 903 in the differentiation of benign from malignant glands in prostate needle biopsies. Histopathology 2002;41:35-41.
54. Mirtti T, Alanen K, Kallajoki M, et al. Expression of cystatins, high molecular weight cytokeratin, and proliferation markers in prostatic adenocarcinoma and hyperplasia. Prostate 2003;54:290-8.
55. Rehman I, Cross SS, Azzouzi AR, et al. S100A6 (calcyclin) is a prostate basal cell marker absent in prostate cancer and its precursors. Br J Cancer 2004;91:739-44.
56. Shah RB, Kunju LP, Shen R, et al. Usefulness of basal cell cocktail (34betaE12+p63) in the diagnosis of atypical prostate glandular proliferations. Am J Clin Pathol 2004;122:517-23.
57. Zhou M, Shah R, Shen R, et al. Basal cell cocktail (34betaE12+p63) improves the detection of prostate basal cells. Am J Surg Pathol 2003;27:365-71.
58. Yang XJ, Wu CL, Woda BA, et al. Expression of alpha-methylacyl-CoA racemase (P504S) in atypical adenomatous hyperplasia of the prostate. Am J Surg Pathol 2002;26:921-5.
59. Rubin MA, Zhou M, Dhanasekaran SM, et al. (Alpha)-methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. JAMA 2002;287:1662-70.
60. Beach R, Gown AM, de Peralta-Venturina MN, et al. P504S immunohistochemical detection in 405 prostatic specimens including 376 18-gauge needle biopsies. Am J Surg Pathol 2002;26:1588-96.
61. Jiang Z, Wu C-L, Woda BA, et al. P504S/alpha-methylacyl-CoA racemase A useful marker for diagnosis of small foci of prostatic carcinoma on needle biopsy. Am J Surg Pathol 2002;26:1169-74.
62. Magi-Galluzzi C, Luo J, Issacs WB, et al. Alpha-methylacyl-CoA racemase: a variably sensitive immunohistochemical marker for the diagnosis of small cancer foci on needle biopsy. Am J Surg Pathol 2003;27:1128-33.
63. Jiang Z, Woda B, Rock KL, et al. P504S: a new molecular marker for the detection of prostate carcinoma. Am J Surg Pathol 2001;25:1397-404.
64. Wu CL, Yang XJ, Tretiakova M, et al. Analysis of alpha-methylacyl-CoA racemase (P504S) expression in high-grade prostatic intraepithelial neoplasia. Hum Pathol 2004;35:1008-13.
65. Sanderson SO, Sebo TJ, Murphy LM, et al. An analysis of the p63/alpha-methylacyl coenzyme A racemase immunohistochemical cocktail stain in prostate needle biopsy specimens and tissue microarrays. Am J Clin Pathol 2004;121:220-5.
66. Molinie V, Fromont G, Sibony M, et al. Diagnostic utility of p63/alpha-methyl-CoA-racemase (p504s) cocktail in atypical foci in the prostate. Mod Pathol 2004;17:1180-90.
67. Hameed O, Sublett J, Humphrey PA. Immunohistochemical stains for p63, alpha-methylacyl-CoA racemase, versus a cocktail comprising both, in the diagnosis of prostatic carcinoma: a comparison of the immunohistochemical staining or 430 foci in radical prostatectomy and needle biopsy tissues. Am J Surg Pathol 2005;29:579-87.
68. Hameed O, Humphrey PA. P63/AMACR antibody cocktail restaining of prostate needle biopsy tissues after transfer to charged slides: a viable approach in the diagnosis of small atypical foci that are lost on block sectioning. Am J Clin Pathol 2005;124:708-15.
69. Jiang Z, Li C, Fischer A, et al. Using an AMACR (P504S)/34betaE12/p63 cocktail for the detection of small focal prostate carcinoma in needle biopsy specimens. Am J Clin Pathol 2005;123:231-6.
70. Ruska KM, Sauvageot J, Epstein JI. Histology and cellular kinetics of prostatic atrophy. Am J Surg Pathol 1998;22:1073-7.
71. Presti B, Weidner N. Granulomatous prostatitis and poorly differentiated prostate carcinoma. Their distinction with the use of immunohistochemical methods. Am J Clin Pathol 1991;95:330-4.
72. Epstein JI, Potter SR. The pathologic interpretation and significance of prostate biopsy findings: implications and current controversies. J Urol 2001;166:402-10.
73. Amin MB, Boccon-Gibod L, Egevad L, et al. Prognostic and predictive factors and reporting of prostate carcinoma in prostate needle biopsy specimens. Scand J Urol Nephrol 2005;216(Suppl):20-33.
74. Bismar TA, Lewis JS Jr, Vollmer RT, et al. Multiple measures of carcinoma extent versus perineural invasion in prostate needle biopsy tissue in prediction of pathologic stage in a screening population. Am J Surg Pathol 2003;27:432-40.